The word “lesson” gets a bad rep. We associate it with a formal classroom setting, automatically giving many PTSD of homework and school. That goes doubly for the Hebrew equivalent of the word “lesson ...

Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple ...

Eli Lilly is already a market leader in the GLP-1 market, but its high valuation could limit future gains. Viking Therapeutics doesn't have an approved product just yet, but VK2735 has shown a lot of ...

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.

When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the ...

Add Yahoo as a preferred source to see more of our stories on Google. Computer guy TikTok prank and meme explained. If you've spent any time online over the last few weeks, you've probably seen a ...

View post: FDA recall hits 2.5 million bottles of widely used eye drops ...

While Novo Nordisk was first to market with GLP-1 weight-loss drugs, it faced supply constraints. That opened the U.S. market up to generic competition earlier than normal, hampering the company's ...

Eli Lilly LLY2.96%increase; up pointing triangle signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.

Pharmaceutical giant Eli Lilly plans to buy a biotechnology company in Bothell for $1.5 billion. The acquisition of Curevo Vaccine, which develops vaccines for shingles and chickenpox, was announced ...

Eli Lilly has successfully challenged Noom’s “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the ...

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.